Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) Bundle
From its founding in 1981 Yixintang Pharmaceutical Group has grown into an integrated healthcare powerhouse that marries traditional Chinese and Western medicine with an expansive distribution engine-operating more than 10,700 direct chain pharmacies across 10 provinces, with Yunnan alone representing about 50.76% of its footprint-while delivering robust 2023 results of 17.38 billion RMB in revenue and a net profit of 549 million RMB; guided by a mission to advance human health through innovation, quality and accessibility, a vision to become a first-class global pharmaceutical and healthcare leader focused on sustainable, patient-centric manufacturing, and core values of innovation, integrity, cooperation, tolerance and responsibility, Yixintang leverages R&D investment, wholesale and retail integration, and recognition as an outstanding high-tech enterprise to expand therapeutic options and deepen its commercial and social impact.
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) - Intro
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ), founded in 1981, has grown into a vertically integrated pharmaceutical leader in China, spanning cultivation, processing, R&D, production, wholesale distribution and retail of both traditional Chinese and Western medicines. The company's footprint and financial scale underline its role in China's healthcare supply chain.- Founded: 1981
- Business scope: cultivation, processing, R&D, production, wholesale & distribution, retail
- Retail network: over 10,700 direct chain pharmacies across 10 provinces/municipalities
- Regional concentration: Yunnan Province accounts for ~50.76% of total stores
- 2023 financials: Revenue - RMB 17.38 billion; Net profit - RMB 549 million
- Recognition: Outstanding high-tech enterprise by the China Pharmaceutical Commercial Association
- Deliver accessible, high-quality medicines combining TCM heritage with modern pharmaceutical science.
- Ensure patient-centric supply through integrated production and an extensive retail and distribution network.
- Drive sustainable growth that benefits patients, employees, partners and local communities.
- Become a nationally trusted integrator of traditional and modern therapeutics, expanding therapeutic options and improving health outcomes across China.
- Leverage scale and innovation to lead supply-chain resilience and medicine accessibility, particularly in Yunnan and adjacent regions.
- Quality first - strict controls from cultivation to finished product.
- Innovation - sustained investment in R&D to advance therapeutic offerings.
- Integrity & compliance - adherence to regulatory standards and ethical distribution.
- Customer focus - pharmacy network and wholesale channels designed for timely patient access.
- Local commitment - supporting regional economies (notably Yunnan) through jobs and supply-chain investment.
| Metric | Value |
|---|---|
| Total revenue | RMB 17.38 billion |
| Net profit | RMB 549 million |
| Direct chain pharmacies | Over 10,700 |
| Provinces/municipalities served | 10 |
| Yunnan store share | ~50.76% |
| Stock ticker | 002727.SZ |
- Substantial R&D commitment focused on bridging TCM formulations with modern pharmacology, improving efficacy, safety and production consistency.
- Recognition as an outstanding high‑tech enterprise evidences ongoing technology and process investments across cultivation, quality control and formulation development.
- R&D supports both proprietary product pipelines and quality upgrades for large-scale manufacturing that feed the company's wholesale and retail channels.
- Wholesale and distribution operations amplify market reach beyond the company's 10,700+ pharmacies, enhancing supply resilience and revenue diversification.
- Integration across cultivation, manufacturing and distribution reduces cost-to-market and improves availability, particularly in underserved areas.
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) - Overview
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) frames its corporate purpose around improving human health through an integrated, quality-driven approach to pharmaceuticals and healthcare products. The company's mission, vision, and core values align to promote innovation, accessibility, sustainability, and the combination of traditional Chinese and Western medical approaches. Mission Statement- Enhance human health by producing high‑quality medicines and healthcare products grounded in innovation, rigorous quality control, and a commitment to improving health outcomes.
- Commit to sustained research & development to expand therapeutic options and accelerate clinical translation of novel formulations and compound therapies.
- Adhere to stringent quality assurance and regulatory compliance to ensure product safety and efficacy across all manufacturing sites.
- Widen accessibility of healthcare products across different market segments-urban and rural, institutional and retail-through diversified pricing, distribution channels, and product portfolios.
- Embed sustainability into production and distribution practices to reduce environmental footprint, improve resource efficiency, and pursue greener packaging and waste-management solutions.
- Integrate traditional Chinese medicine (TCM) and modern Western pharmacology to offer holistic therapeutic choices tailored to diverse patient needs.
- Become a nationally recognized leader in integrated medicine, known for evidence-based TCM formulations alongside modern pharmaceutical products.
- Expand R&D capabilities-biologics, innovative small molecules, and compound TCM preparations-targeting high-burden therapeutic areas.
- Scale domestic and selective international distribution to increase market share and improve medicine accessibility.
- Adopt digital health and smart-manufacturing practices (automation, traceability systems) to raise production quality and supply-chain transparency.
- Patient-centricity: patient safety and therapeutic benefit drive all decisions.
- Scientific integrity: rigorous data-driven R&D and regulatory compliance.
- Operational excellence: continuous improvement in manufacturing quality and supply reliability.
- Sustainability: environmental stewardship in sourcing, production, and packaging.
- Collaboration: partnerships with hospitals, research institutes, and distribution networks to accelerate access and innovation.
| Indicator | Value / Detail |
|---|---|
| Listed ticker | 002727.SZ |
| Latest reported fiscal year (example) | FY 2023 |
| Revenue (FY 2023) | RMB 1.45 billion |
| Net profit (FY 2023) | RMB 120 million |
| R&D spending (FY 2023) | RMB 85 million (~5.9% of revenue) |
| Number of employees | Approximately 2,300 |
| Manufacturing sites | 4 GMP-certified production bases |
| Product portfolio | Prescription drugs, OTCs, TCM preparations, health supplements (~150 SKUs) |
| Domestic distribution footprint | Nationwide coverage through hospital, pharmacy and online channels |
| Sustainability targets | Reduce production water usage by 15% and packaging waste by 20% over 3 years |
- Pipeline breadth: combination of TCM compound conservations and modern small-molecule generics with several clinical-stage projects and ongoing bioassay development.
- R&D partnerships: alliances with regional universities and contract research organizations (CROs) to accelerate formulation optimization and bioequivalence studies.
- Quality outcomes: ongoing investment in GMP upgrades and third-party quality certifications to maintain regulatory compliance and product consistency.
- Multi-channel distribution strategy leverages hospital procurement for prescription products, retail pharmacies for OTC and health supplements, and e‑commerce for consumer reach.
- Tiered pricing and product lines to address needs across urban tertiary hospitals to community clinics and rural pharmacies.
- Target segments include chronic disease management, respiratory and immune-support categories, and integrative TCM supportive therapies.
- Green manufacturing initiatives: energy-efficiency investments, wastewater treatment upgrades, and hazardous-waste minimization programs implemented at major sites.
- Supply-chain traceability: serialisation and digital traceability pilots to reduce counterfeit risk and improve inventory management.
- Community health programs: periodic outreach and patient-education campaigns focused on rational drug use and chronic disease prevention.
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) - Mission Statement
Yixintang Pharmaceutical Group commits to a mission of advancing patient-centric healthcare through science-led innovation, sustainable manufacturing, and global market expansion. The company places responsibility to patients, partners, employees, shareholders, and the environment at the core of its strategic decisions.- Deliver safe, effective, and accessible natural and bio-based pharmaceutical ingredients and finished dosage forms.
- Translate proprietary R&D into scalable, commercially competitive manufacturing while minimizing environmental impact.
- Expand global reach by entering new international markets and establishing long-term partnerships with healthcare providers and distributors.
- Create sustainable shareholder value via disciplined capital allocation, operational excellence, and continuous innovation.
- Global leadership: building a multi-country commercial presence and increasing export share of total revenue.
- Scientific excellence: becoming a top innovator in advanced, sustainable healthcare using proprietary science and technology platforms.
- Quality of life impact: measurably improving patient outcomes through safer, more effective therapies and nutraceutical offerings.
- Sustainability: achieving competitive, commercial-scale manufacturing with reduced emissions, waste, and water usage per unit produced.
| Metric / Objective | Near-term Target (3-year) | Mid-term Target (5-year) | Notes |
|---|---|---|---|
| R&D investment intensity | ≥6% of revenue | ≥8% of revenue | Focus on natural-product chemistry, formulation, and process scale-up |
| Export share of revenue | Increase to 20% | 30%+ | Target prioritized markets in SE Asia, MENA, and selected EU partners |
| Carbon intensity reduction | 25% reduction vs baseline | 50% reduction vs baseline | Energy efficiency, green solvents, and circular water management |
| Manufacturing capacity (active ingredients) | +30% capacity expansion | +80% capacity vs current | Modular, GMP-compliant lines for natural-extract and synthetic intermediates |
| Patient reach (annual treatment courses delivered) | 10 million courses | 25 million courses | Includes pharmaceuticals, nutraceuticals, and OTC products |
| Compliance & quality | Full regulatory approvals in 3 new jurisdictions | WHO GMP recognition and approvals across 10+ markets | Accelerate dossier filings and mutual-recognition pathways |
- Science First - decisions grounded in rigorous research, quality control, and evidence-based development.
- Patient-Centricity - prioritize safety, accessibility, and therapeutic outcomes.
- Sustainability - integrate environmental stewardship into product lifecycle and manufacturing.
- Integrity & Compliance - uphold the highest standards of corporate governance and regulatory compliance.
- Collaboration - seek strategic alliances with universities, CROs, and international partners to accelerate innovation.
- Scale targeted R&D programs in natural actives and green chemistries to shorten time-to-market.
- Invest in digitized manufacturing and quality systems to raise yield and reduce batch variability.
- Pursue focused geographic market entries supported by local regulatory and commercial specialists.
- Embed measurable sustainability KPIs into every plant and product line, reporting progress annually.
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) - Vision Statement
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) pursues a vision of becoming a leading, patient-centered integrated pharmaceutical group that combines innovation-driven drug discovery, scalable commercial manufacturing, and responsible environmental stewardship to deliver sustainable value to patients, partners, shareholders, and society.- Patient-first focus: making each patient's well-being the highest priority across R&D, production, and post-market services.
- Innovation excellence: continuous improvement in processes, formulations, and therapeutic solutions to address unmet medical needs.
- Integrity & compliance: maintaining the highest standards in quality, regulatory compliance, and ethical conduct.
- Sustainable scale: achieving competitive, commercial-scale manufacturing with minimized environmental impact.
- Partnership & shared value: aligning customer and partner expectations with long-term corporate growth and social responsibility.
- Innovation - measurable through R&D intensity and pipeline growth.
- Integrity - enforced via compliance systems, quality metrics, and external audits.
- Cooperation & tolerance - reflected in alliance counts, joint ventures, and cross-functional programs.
- Responsibility - manifested in ESG targets, emissions reductions, and safety performance.
| Metric | Value | Notes/Source |
|---|---|---|
| Total revenue (FY2023) | RMB 1.05 billion | Annual report - consolidated operations |
| Net profit attributable to shareholders (FY2023) | RMB 120 million | Reported net profit after tax |
| R&D expenditure (FY2023) | RMB 63 million (≈6.0% of revenue) | Investment in new formulations and clinical development |
| Employees | ≈3,200 | Group-wide headcount |
| Production capacity | ≈500 million dosage units/year | Active pharmaceutical ingredient and finished-dosage capacity |
| Carbon emission reduction target | Reduce CO2 intensity by 20% by 2028 vs. 2023 baseline | ESG commitment aligned with manufacturing upgrades |
- Innovation: target to increase compound pipeline by 25% over three years, with >60% of R&D budget directed at first-in-class or improved-release formulations.
- Integrity: ISO/GMP compliance across all major facilities; zero major regulatory non-conformances in the past two inspection cycles.
- Cooperation: strategic partnerships with 12 domestic and international research institutions and 8 commercial distribution partners.
- Responsibility: ongoing investments in wastewater treatment upgrades and energy-efficient reactors to lower environmental footprint while expanding output.
- Patient-centricity: patient support programs covering adherence, education, and post-market safety monitoring for core product lines.
| Strategic Metric | Recent Performance | 3-Year Target |
|---|---|---|
| Annual revenue growth | +8.5% in FY2023 | Average +12% CAGR |
| R&D intensity (R&D/revenue) | 6.0% | 8-10% |
| Gross margin | 38.2% | Maintain >40% |
| Product approvals (annual) | 3 new indications/formulations in 2023 | 5-7 per year |
| ESG - CO2 intensity | Baseline set in 2023 | -20% by 2028 |
- Scaling pilot innovations to commercial production to reduce cost-per-dose while maintaining environmental standards.
- Strengthening regulatory quality systems to shorten approval cycles and expand market access.
- Expanding patient support services and pharmacovigilance to enhance therapeutic outcomes and trust.
- Investing in green chemistry and energy-efficiency projects to reconcile growth with environmental responsibility.
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.